PDF(Pubmed)
Abstract：
OBJECTIVE: The aim of this study was to investigate the factors influencing good outcomes in patients receiving only intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.
METHODS: Post hoc exploratory analysis using the RESCUE BT trial identified consecutive patients who received intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke in 55 comprehensive stroke centers from October 2018 to January 2022 in China.
RESULTS: A total of 521 patients received intravenous tirofiban, 253 of whom achieved a good 90-day outcome (modified Rankin Scale [mRS] 0-2). Younger age (adjusted odds ratio [aOR]: 0.965, 95% confidence interval [CI]: 0.947-0.982; p < 0.001), lower serum glucose (aOR: 0.865, 95%CI: 0.807-0.928; p < 0.001), lower baseline National Institutes of Health Stroke Scale (NIHSS) score (aOR: 0.907, 95%CI: 0.869-0.947; p < 0.001), fewer total passes (aOR: 0.791, 95%CI: 0.665-0.939; p = 0.008), shorter punctures to recanalization time (aOR: 0.995, 95%CI:0.991-0.999; p = 0.017), and modified Thrombolysis in Cerebral Infarction (mTICI) score 2b to 3 (aOR: 8.330, 95%CI: 2.705-25.653; p < 0.001) were independent predictors of good outcomes after intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.
CONCLUSIONS: Younger age, lower serum glucose level, lower baseline NIHSS score, fewer total passes, shorter punctures to recanalization time, and mTICI scores of 2b to 3 were independent predictors of good outcomes after intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.
UNASSIGNED: ChiCTR-IOR-17014167.
METHODS: Post hoc exploratory analysis using the RESCUE BT trial identified consecutive patients who received intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke in 55 comprehensive stroke centers from October 2018 to January 2022 in China.
RESULTS: A total of 521 patients received intravenous tirofiban, 253 of whom achieved a good 90-day outcome (modified Rankin Scale [mRS] 0-2). Younger age (adjusted odds ratio [aOR]: 0.965, 95% confidence interval [CI]: 0.947-0.982; p < 0.001), lower serum glucose (aOR: 0.865, 95%CI: 0.807-0.928; p < 0.001), lower baseline National Institutes of Health Stroke Scale (NIHSS) score (aOR: 0.907, 95%CI: 0.869-0.947; p < 0.001), fewer total passes (aOR: 0.791, 95%CI: 0.665-0.939; p = 0.008), shorter punctures to recanalization time (aOR: 0.995, 95%CI:0.991-0.999; p = 0.017), and modified Thrombolysis in Cerebral Infarction (mTICI) score 2b to 3 (aOR: 8.330, 95%CI: 2.705-25.653; p < 0.001) were independent predictors of good outcomes after intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.
CONCLUSIONS: Younger age, lower serum glucose level, lower baseline NIHSS score, fewer total passes, shorter punctures to recanalization time, and mTICI scores of 2b to 3 were independent predictors of good outcomes after intravenous tirofiban with endovascular thrombectomy for large vessel occlusion stroke.
UNASSIGNED: ChiCTR-IOR-17014167.
摘要：
目的：本研究的目的是调查大血管闭塞卒中患者仅接受静脉替罗非班血管内血栓切除术的良好预后的影响因素。
方法：使用RESCUEBT试验的事后探索性分析确定了2018年10月至2022年1月在中国55个综合性卒中中心接受静脉替罗非班血管内血栓切除术治疗大血管闭塞卒中的连续患者。
结果：总共521例患者接受了静脉注射替罗非班，其中253人取得了90天的良好结果(改良的兰金量表[mRS]0-2)。年龄较小（调整后的比值比[aOR]：0.965，95%置信区间[CI]：0.947-0.982；p<0.001），降低血清葡萄糖（aOR：0.865，95CI：0.807-0.928；p<0.001），较低基线美国国立卫生研究院卒中量表(NIHSS)评分(aOR:0.907,95CI:0.869-0.947;p<0.001),总通过次数较少(AOR：0.791，95CI：0.665-0.939；p=0.008)，较短的穿刺至再通时间（aOR：0.995，95CI：0.991-0.999；p=0.017），和改良的脑梗死溶栓（mTICI）评分2b至3（aOR：8.330，95CI：2.705-25.653；p<0.001）是静脉替罗非班联合血管内血栓切除术治疗大血管闭塞卒中后良好结局的独立预测因子。
结论：年龄较小，降低血清葡萄糖水平，较低的基线NIHSS评分，总传球次数较少，更短的穿刺至再通时间，2b~3分的mTICI评分是大血管闭塞卒中患者静脉应用替罗非班血管内血栓切除术后良好结局的独立预测因素.
■ChiCTR-IOR-17014167。
方法：使用RESCUEBT试验的事后探索性分析确定了2018年10月至2022年1月在中国55个综合性卒中中心接受静脉替罗非班血管内血栓切除术治疗大血管闭塞卒中的连续患者。
结果：总共521例患者接受了静脉注射替罗非班，其中253人取得了90天的良好结果(改良的兰金量表[mRS]0-2)。年龄较小（调整后的比值比[aOR]：0.965，95%置信区间[CI]：0.947-0.982；p<0.001），降低血清葡萄糖（aOR：0.865，95CI：0.807-0.928；p<0.001），较低基线美国国立卫生研究院卒中量表(NIHSS)评分(aOR:0.907,95CI:0.869-0.947;p<0.001),总通过次数较少(AOR：0.791，95CI：0.665-0.939；p=0.008)，较短的穿刺至再通时间（aOR：0.995，95CI：0.991-0.999；p=0.017），和改良的脑梗死溶栓（mTICI）评分2b至3（aOR：8.330，95CI：2.705-25.653；p<0.001）是静脉替罗非班联合血管内血栓切除术治疗大血管闭塞卒中后良好结局的独立预测因子。
结论：年龄较小，降低血清葡萄糖水平，较低的基线NIHSS评分，总传球次数较少，更短的穿刺至再通时间，2b~3分的mTICI评分是大血管闭塞卒中患者静脉应用替罗非班血管内血栓切除术后良好结局的独立预测因素.
■ChiCTR-IOR-17014167。
